Kinase inhibitors in CLL: drawing the roadmap

In this issue of Blood, Mato et al report the results of an open-label multicenter phase 2 study of the phosphatidylinositol 3-kinase (PI3K) inhibitor umbralisib in patients with chronic lymphocytic leukemia (CLL) who were intolerant of Bruton tyrosine kinase (BTK) or inhibitors they had received earlier.(1)

Automated summary

Mato et al. reported the results of a phase 2 study on umbralisib, a PI3K inhibitor, in CLL patients who were intolerant of BTK inhibitors. The study suggests that umbralisib may be effective for CLL patients who cannot tolerate BTK inhibitors.